NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/08/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization23,503 mln
Float109 mln
Earnings Date08/10/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.54
Likely reliable
1-Year Forecast
130
Strong upside
Relative Strength
10
/ 100
Significantly lagging
Debt / Equity
0.02
Debt-free
ROE
-6.74
Negative
Business Description
Founded in 2008 and based in Mainz, Germany, BioNTech is a biotechnology company best known for developing one of the first approved mRNA vaccines against COVID-19. Beyond infectious diseases, the company has built a broad pipeline of cancer treatments targeting a wide range of tumor types, spanning lung, breast, colorectal, and several other cancers, with many of these therapies currently in mid-to-late stage clinical trials. BioNTech is also advancing vaccine research for diseases such as tuberculosis, malaria, and mpox, reflecting its ambition to apply its mRNA technology platform across multiple areas of medicine.
